TipRanks
Advertisement
Advertisement

ARCT Stock Latest News

Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
The FlyArcturus Therapeutics price target raised to $41 from $20 at Roth Capital
14d ago
ARCT
VRTX
Arcturus Therapeutics Highlights ARCT-810 Progress at Metabolic Symposium
PremiumCompany Announcements
Arcturus Therapeutics Highlights ARCT-810 Progress at Metabolic Symposium
23d ago
8K
ARCT
Arcturus Therapeutics Earnings Call Balances Progress, Pressure
PremiumCompany Announcements
Arcturus Therapeutics Earnings Call Balances Progress, Pressure
28d ago
ARCT
Arcturus Maintained at Buy as Advancing Pipeline and Strong Cash Position Support Unchanged $23 Price Target
PremiumRatings
Arcturus Maintained at Buy as Advancing Pipeline and Strong Cash Position Support Unchanged $23 Price Target
1M ago
ARCT
Arcturus Therapeutics price target lowered to $20 from $21 at Canaccord
PremiumThe Fly
Arcturus Therapeutics price target lowered to $20 from $21 at Canaccord
1M ago
ARCT
Arcturus Therapeutics reports Q2 EPS (84c), consensus ($1.03)
PremiumThe FlyArcturus Therapeutics reports Q2 EPS (84c), consensus ($1.03)
1M ago
ARCT
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
ARCT
Arcturus Therapeutics: Buy Rating Backed by Advancing mRNA Programs and De-Risked CF Manufacturing Partnership
Premium
Ratings
Arcturus Therapeutics: Buy Rating Backed by Advancing mRNA Programs and De-Risked CF Manufacturing Partnership
2M ago
ARCT
Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
PremiumThe Fly
Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
3M ago
TMO
ARCT
Arcturus Therapeutics Announces Thermo Fisher mRNA Partnership
PremiumCompany Announcements
Arcturus Therapeutics Announces Thermo Fisher mRNA Partnership
3M ago
8K
ARCT
Arcturus announces collaboration with Thermo Fisher to advance ARCT-032
PremiumThe Fly
Arcturus announces collaboration with Thermo Fisher to advance ARCT-032
3M ago
TMO
ARCT
Arcturus Therapeutics initiated with a Buy at Freedom Broker
PremiumThe Fly
Arcturus Therapeutics initiated with a Buy at Freedom Broker
3M ago
ARCT
Arcturus Shareholders Back Board, Pay, and Auditor
PremiumCompany AnnouncementsArcturus Shareholders Back Board, Pay, and Auditor
3M ago
8K
ARCT
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
Premium
Company Announcements
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
4M ago
ARCT
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
Premium
Ratings
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
4M ago
ARCT
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
PremiumRatings
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
4M ago
ARCT
Arcturus Therapeutics Signals Progress Amid Revenue Slip
PremiumCompany Announcements
Arcturus Therapeutics Signals Progress Amid Revenue Slip
4M ago
ARCT
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
PremiumRatings
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
4M ago
ARCT
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
PremiumCompany Announcements
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
4M ago
8K
ARCT
Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
PremiumThe FlyArcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)
4M ago
ARCT
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
ARCT
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
Premium
Market News
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
5M ago
WGS
ARCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >